Stockscreener 앱 받기
13.87
1.09%
0.15
시간 외 거래:
13.70
-0.17
-1.23%
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings - MarketBeat
Understanding Momentum Shifts in (ORIC) - Stock Traders Daily
AVLN Stock Price and Chart — NASDAQ:AVLN - TradingView
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ - TradingView
What is HC Wainwright's Forecast for ORIC Q1 Earnings? - MarketBeat
ORIC Pharmaceuticals, Inc. (ORIC) options chain - Yahoo Finance Australia
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25 - webull.com
ORIC Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress - Investing.com
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally - Sahm
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? - Yahoo Finance
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Promising Biotech with 60% Upside Potential - DirectorsTalk Interviews
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC? - Sahm
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25 - moomoo.com
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 12.3% HigherHere's What Happened - MarketBeat
Stock Traders Purchase High Volume of Put Options on Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals (ORIC) Projected to Release Earnings on Tuesday - MarketBeat
ORIC SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
ORIC Pharmaceuticals (ORIC) Launches Pivotal Phase 3 Trial Amid Mixed Market Signals - GuruFocus
Oric Pharmaceuticals, Inc. 6M 2026: Net loss $(77.3M), Diluted EPS $(0.72) — 10-Q Summary - TradingView
ORIC: Net loss rose to $77.3M as R&D spending increased; cash runway extends into H2 2028 - TradingView
ORIC: Advanced late-stage oncology pipeline with strong cash position and key trials underway - TradingView
Oric Pharmaceuticals reports Q2 2026 net loss $41.5M, cash $387.6M; Phase 3 trial initiated - TradingView
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - The Manila Times
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2%Should You Sell? - MarketBeat
Defilade Capital Management L.P. Purchases Shares of 842,928 Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Avoiding Lag: Real-Time Signals in (ORIC) Movement - Stock Traders Daily
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan - The Globe and Mail
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 77.77% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
Vivo Capital LLC Cuts Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oric Pharmaceuticals (ORIC) director trades options, sells 13,100 shares - Stock Titan
Oric Pharmaceuticals Inc (ORIC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oric Pharmaceuticals Inc (ORIC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oric Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ORIC - TradingView
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ORIC|Oric Pharmaceuticals Inc|Price:13.500|Chg%:+0.570 - TradingKey
Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210 - TradingKey
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey
Does ORIC (ORIC) Retaining Rinzimetostat Rights Hint At A High-Conviction, High-Risk Development Strategy? - Sahm
Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4%Time to Buy? - MarketBeat
Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (ORIC) Stock Analysis: A Biotech Gem With An 86% Upside Potential - DirectorsTalk Interviews
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha
Oric Pharmaceuticals stock trades down to 10.69 as oricpharma promotes BTIG conference meeting - Traders Union
Discipline and Rules-Based Execution in ORIC Response - Stock Traders Daily
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - The Manila Times
ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire
How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - Sahm
ORIC Launches Phase 3 Himalayas-1 Trial - t.co
0.52%
0.07%
자본화:
|
볼륨(24시간):